Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Feb:85:104675.
doi: 10.1016/j.breast.2025.104675. Epub 2025 Dec 12.

Impact of the interruption of tamoxifen for pregnancy on the recurrence and survival outcomes among young women with breast cancer

Chihwan David Cha  1 , Somin Jeon  2 , Jihyun Keum  3 , Shin Jeong Pak  1 , Boyoung Park  4 , Min Sung Chung  5
Affiliations

Impact of the interruption of tamoxifen for pregnancy on the recurrence and survival outcomes among young women with breast cancer

Chihwan David Cha et al. Breast. 2026 Feb.

Abstract

Background: Young survivors of breast cancer often consider pregnancy after completing or interrupting endocrine therapy. However, concerns remain regarding the safety of tamoxifen interruption for pregnancy and its impact on survival outcomes. We aimed to evaluate the impact of interrupting and resuming tamoxifen for pregnancy on recurrence and mortality in patients with breast cancer, using real-world data.

Methods: We conducted a retrospective cohort study using data from the Korean National Health Insurance Service National Health Information Database. Among 32,378 women aged 18-45 years diagnosed with invasive breast cancer and who underwent surgery between 2009 and 2014, patients were categorized into groups based on tamoxifen interruption and pregnancy: Group 1 (interruption and resumption, n = 126), Group 2 (interruption without resumption, n = 261), Group 3 (initiation of tamoxifen after childbirth, n = 41), and Control (no interruption nor pregnancy, n =428). The control group was age-matched to the interruption groups in a 1:1 ratio. Clinical outcomes, including recurrence and mortality, were compared among groups.

Results: Over a median follow-up of 8.5 years, Groups 1 and 2 showed significantly lower risks of recurrence than the control group did (hazard ratio [HR] 0.41, 95 % confidence interval [CI]: 0.22-0.76, P = 0.005; HR 0.30, 95 % CI: 0.18-0.50, P < 0.001). In multivariate analysis, Group 2 also showed better survival outcomes (HR 0.18, 95% CI: 0.08-0.41, P < 0.001). Pregnancy outcomes differed across groups: Groups 1 and 2 had higher rates of full-term pregnancies, whereas Group 3 had a significantly higher abortion rate (23.8 %, 23.4 % vs. 56.1 %, respectively).

Conclusion: These findings suggest that temporary tamoxifen interruption for pregnancy may be a viable option for young survivors of breast cancer. Further studies are warranted to clarify the long-term impact of tamoxifen interruption on prognosis.

Keywords: Breast cancer; Endocrine therapy; Pregnancy; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Study schema.
Fig. 2
Fig. 2
Consort diagram for the analysis population.
Fig. 3
Fig. 3
Survival curves of breast cancer recurrence and overall mortality. Blue line: Group 1, Green line: Group 2, Red line: Group 3, Black line: Controls.
See this image and copyright information in PMC

References

    1. Bray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. - PubMed
    1. Arnold M., Morgan E., Rumgay H., et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. - PMC - PubMed
    1. Heer E., Harper A., Escandor N., Sung H., McCormack V., Fidler-Benaoudia M.M. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–e1037. - PubMed
    1. Rosenberg S.M., Newman L.A., Partridge A.H. Breast cancer in young women: rare disease or public health problem? JAMA Oncol. 2015;1(7):877–878. - PubMed
    1. de Kermadec E., Zheng Y., Rosenberg S., et al. Fertility concerns and treatment decision-making among national sample of young women with breast cancer. Cancer Med. 2024;13(1) - PMC - PubMed